ArticleMaterials today. Bio2026
Engineering oral celastrol-polysaccharide supramolecular nanoassemblies across intestinal barriers for the intervention of nonalcoholic steatohepatitis.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The development of effective oral therapies for nonalcoholic steatohepatitis (NASH) remains a critical unmet need in clinical practice. Celastrol (CEL), a potent natural compound, is a promising candidate for NASH due to its lipid-modulating, anti-inflammatory properties, and antioxidative properties. However, its clinical translation is severely hindered by poor oral bioavailability and a narrow therapeutic window stemming from significant toxicity. To overcome these limitations, we present the design and fabrication of novel, carrier-free CEL nanoparticles stabilized through natural polysaccharide self-assembly. This innovative formulation strategy is aimed at substantially enhancing the oral bioavailability of CEL, thereby augmenting its therapeutic efficacy in NASH while mitigating associated adverse effects. In this study, we developed a polysaccharide-CEL supramolecular depot comprising 42 distinct nanoassemblies for oral delivery in NASH, identifying chondroitin sulfate (CS) as the optimal polysaccharide adjuvant. The resulting CS/CNA formulation markedly improved oral absorption, with a 3.12-fold increase in observed systemic exposure based on AUC
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.